learningcurve2020
6 minutes ago
There are a dozen reasons the market cap could hover at this level even after a possible MHRA approval. From partial approval, or some small patient subset to chase, or NICE refusing to pay, or no real profit model in the UK, to Real world data accumulation before full nod, to Advent taking profi